These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35324976)

  • 41. Efficacy of Tripterygium wilfordii Hook F on animal model of Diabetic Kidney Diseases: A systematic review and meta-analysis.
    Jin D; Yu M; Li X; Wang X
    J Ethnopharmacol; 2021 Dec; 281():114536. PubMed ID: 34419607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial.
    Brandt-Jacobsen NH; Johansen ML; Rasmussen J; Forman JL; Holm MR; Faber J; Rossignol P; Schou M; Kistorp C
    Diabetes Metab; 2021 Jul; 47(4):101190. PubMed ID: 32919068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy.
    Goenka L; Padmanaban R; George M
    Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI/ARBs in patients with diabetic kidney disease.
    An J; Niu F; Sim JJ
    Pharmacotherapy; 2021 Dec; 41(12):998-1008. PubMed ID: 34655484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
    Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL
    Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Huangqi Guizhi Wuwu Decoction for treating diabetic peripheral neuropathy: a meta-analysis of 16 randomized controlled trials.
    Pang B; Zhao TY; Zhao LH; Wan F; Ye R; Zhou Q; Tian F; Tong XL
    Neural Regen Res; 2016 Aug; 11(8):1347-58. PubMed ID: 27651785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Should we add atorvastatin to irbesartan for improving renoprotective effects in early diabetic nephropathy? A meta-analysis of randomized controlled trials.
    Zuo Y; Li T; Lei Z
    Pharmacol Res; 2019 Aug; 146():104286. PubMed ID: 31152787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Suoquan pill for the treatment of diabetic nephropathy: A protocol for systematic review and meta-analysis.
    Cai P; Wu Z; Huang W; Niu Q; Zhu Y; Yin D
    Medicine (Baltimore); 2021 Apr; 100(17):e25613. PubMed ID: 33907114
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and Safety of Zhenwu Decoction in the Treatment of Diabetic Nephropathy: A Systematic Review and Meta-Analysis.
    Lv X; Zhou M; Liu X; Xiang Q; Yu R
    Evid Based Complement Alternat Med; 2022; 2022():2133705. PubMed ID: 36387355
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.
    Boesby L; Elung-Jensen T; Klausen TW; Strandgaard S; Kamper AL
    PLoS One; 2011; 6(11):e26904. PubMed ID: 22073219
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Mali N; Su F; Ge J; Fan WX; Zhang J; Ma J
    BMC Endocr Disord; 2022 Apr; 22(1):93. PubMed ID: 35392872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of Salvia miltiorrhiza (Salvia miltiorrhiza Bunge) and ligustrazine injection in the adjuvant treatment of early-stage diabetic kidney disease: A systematic review and meta-analysis.
    Xie F; Zhang B; Dai S; Jin B; Zhang T; Dong F
    J Ethnopharmacol; 2021 Dec; 281():114346. PubMed ID: 34153447
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antioxidant for treatment of diabetic nephropathy: A systematic review and meta-analysis.
    Kandhare AD; Mukherjee A; Bodhankar SL
    Chem Biol Interact; 2017 Dec; 278():212-221. PubMed ID: 29108777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
    Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M
    Am J Kidney Dis; 2016 Oct; 68(4):591-598. PubMed ID: 27265777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Guo J; Chen H; Zhang X; Lou W; Zhang P; Qiu Y; Zhang C; Wang Y; Liu WJ
    Oxid Med Cell Longev; 2021; 2021():2074610. PubMed ID: 34956436
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic effects of Yiqi Huoxue prescription on diabetic nephropathy: a meta-analysis and systematic review.
    Ye C; Gu L; Feng Y; Zhou F; She W
    Ann Palliat Med; 2021 Jun; 10(6):6617-6629. PubMed ID: 34154340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of antiplatelet drugs for the prevention of diabetic nephropathy: A meta-analysis of randomized controlled trials
.
    Chen G; Huang W; Hong S; Li X; Su B; Li X; Tang S
    Clin Nephrol; 2018 Dec; 90(6):419-426. PubMed ID: 30378535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and Safety of Wuling Powder in the Treatment of Patients with Diabetic Nephropathy: A Systematic Review and Meta-Analysis.
    Yang Y; Sha W; Hou K; Xu Y; Tan S; Yin H; Chen L; Lei T
    Evid Based Complement Alternat Med; 2022; 2022():1720749. PubMed ID: 36212947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.